Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
월요일, 8월 31

Adaptive Biotechnologies Corp

ADPTNASDAQ
Trade with Public
Trade with Public
$23.74
-1.45-5.76%
마지막 업데이트: Aug 31, 9:29 AM
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Adaptive Biotechnologies Analyst Price Targets

Wall Street analyst price targets and consensus rating for Adaptive Biotechnologies (ADPT).

Price Target Range — 12 Quarters

Analyst Consensus — 7 Analysts

7Buy
Consensus RatingBuy# Analysts7Avg. Consensus PT$20Upside to Avg. PT-14.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 4, 2026Piper SandlerDavid WestenbergPT RaiseOverweight$20→$28
Jul 30, 2026Morgan StanleyTejas SavantPT RaiseEqual-Weight$20→$22
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $27.5

Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and raises the price target from $20 to $27.5.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $22

Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $20 to $22.
Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $28

TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $25 to $28.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $25

Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $22 to $25.
Benzinga Newsdesk

PRO
BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $25

BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $24 to $25.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $20

Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $18 to $20.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved